These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Campoli M; Ferrone S Expert Rev Vaccines; 2004 Apr; 3(2):171-87. PubMed ID: 15056043 [TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of malignant melanoma--basic principles and novel therapeutic approaches]. Enk AH; Becker JC; Schuler G J Dtsch Dermatol Ges; 2006 Aug; 4(8):635-45. PubMed ID: 16895565 [TBL] [Abstract][Full Text] [Related]
8. Vaccination: role in metastatic melanoma. Pilla L; Valenti R; Marrari A; Patuzzo R; Santinami M; Parmiani G; Rivoltini L Expert Rev Anticancer Ther; 2006 Aug; 6(8):1305-18. PubMed ID: 16925496 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814 [TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
12. [Advances in cellular immunotherapy for malignant melanoma]. López M; Escobar A; Alfaro J; Fodor M; Larrondo M; Ferrada C; Salazar-Onfray F Rev Med Chil; 2004 Sep; 132(9):1115-26. PubMed ID: 15543770 [TBL] [Abstract][Full Text] [Related]
17. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Gajewski TF; Louahed J; Brichard VG Cancer J; 2010; 16(4):399-403. PubMed ID: 20693853 [TBL] [Abstract][Full Text] [Related]
18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
19. Melanoma vaccines: achievements and perspectives. Brichard VG; Gérard C Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881 [TBL] [Abstract][Full Text] [Related]
20. New strategies to improve the efficacy of colorectal cancer vaccines: from bench to bedside. Mocellin S Curr Opin Investig Drugs; 2006 Dec; 7(12):1052-61. PubMed ID: 17209522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]